300 Third Street, First Floor
About Editas Medicine
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu
CEO: Karine Bosley
CFO: Andrew Hack
COO: Alexandra Glucksmann
CTO: Vic Myer
Please click here for Editas Medicine job opportunities.
FOLLOW EDITAS MEDICINE:
Tweets by Editas Medicine
124 articles with Editas Medicine
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conferenc
GenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery
GenEdit has developed a comprehensive delivery system for CRISPR-based therapeutics, including gene knockout and gene repair therapies, to enable safer delivery options with improved efficiency.
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Data support novel approach to develop a best-in-class, durable medicine for people living with hemoglobinopathies
Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells
Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Tuesday, November 12, 2019, at 8:00 a.m. ET to discuss a corporate update and results for the third quarter of 2019.
Editas Medicine, Inc., a leading genome editing company, announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately.
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
This collaboration brings together AskBio’s leading capsid development, clinical stage AAV vector delivery system, and manufacturing expertise with Editas Medicine’s leading genome editing technologies to potentially develop novel medicines for patients with high unmet need.
Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.
March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies and solid tumors.
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Shares of Cambridge, Mass.-based Editas Medicine are down nearly 20 percent after Chief Executive Officer Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
10/31/2018It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Cambridge, Mass.-based Editas Medicine, one of the leading CRISPR gene editing companies, is losing its chief medical officer. Gerald Cox will step down from his role at the end of the year.